title: Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa.
authors.forename: A
authors.initials: A
authors.lastname: Italiano
authors.forename: C
authors.initials: C
authors.lastname: Delcambre
authors.forename: I
authors.initials: I
authors.lastname: Hostein
authors.forename: A L
authors.initials: AL
authors.lastname: Cazeau
authors.forename: M
authors.initials: M
authors.lastname: Marty
authors.forename: A
authors.initials: A
authors.lastname: Avril
authors.forename: J-M
authors.initials: JM
authors.lastname: Coindre
authors.forename: B
authors.initials: B
authors.lastname: Bui
mesh_terms: D005260:Female; D006338:Heart Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D054973:Perivascular Epithelioid Cell Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology
chemical_list: D047908:Intracellular Signaling Peptides and Proteins; D047428:Protein Kinase Inhibitors; C401859:temsirolimus; C546842:MTOR protein, human; D017346:Protein Serine-Threonine Kinases; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus